𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Imatinib mesylate causes growth plate closure in vivo

✍ Scribed by Vandyke, K; Dewar, A L; Fitter, S; Menicanin, D; To, L B; Hughes, T P; Zannettino, A C W

Book ID
109886899
Publisher
Nature Publishing Group
Year
2009
Tongue
English
Weight
308 KB
Volume
23
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Imatinib mesylate causes hypopigmentatio
Imatinib mesylate causes hypopigmentation in the skin
✍ Anne S. Tsao; Hagop Kantarjian; Jorge Cortes; Susan O'Brien; Moshe Talpaz πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 218 KB

## Background: Imatinib mesylate is a tyrosine kinase inhibitor that targets the bcr-abl protein in cml, c-kit (kit) and platelet-derived growth factor receptors. in clinical trials with imatinib mesylate, common side effects of nausea, emesis, diarrhea, periorbital edema, fluid retention, and myel

Imatinib mesylate causes hypopigmentatio
Imatinib mesylate causes hypopigmentation in the skin
✍ Kin Wah Leong; Thoong Chow Lee; Ai Sim Goh πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 69 KB

## Cancer-Related Fatigue: Evolving Concepts in Evaluation and Treatment I n their otherwise excellent review of cancer-related fatigue, Stasi et al. 1 failed to discuss opioid-induced androgen deficiency (OPIAD), an extremely common and easily identified cause of fatigue in men with malignant dis